ProfileGDS5678 / 1424795_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 8% 9% 9% 9% 9% 10% 8% 9% 9% 9% 9% 9% 9% 9% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.223318
GSM967853U87-EV human glioblastoma xenograft - Control 22.215029
GSM967854U87-EV human glioblastoma xenograft - Control 32.218169
GSM967855U87-EV human glioblastoma xenograft - Control 42.163879
GSM967856U87-EV human glioblastoma xenograft - Control 52.181379
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.3049810
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.210618
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.196729
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.196469
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.207659
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.19819
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.199589
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.210819
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.204059